Back to Dashboard








Regeneron Pharmaceuticals, Inc. (REGN)
Real-time intraday values
Market Overview
From:
To:
REGN Intraday
No data available
SymbolREGN
IPO DateApr 2, 1991
CEODr. Leonard S. Schleifer M.D., Ph.D.
Full Time Employees15.4k
SectorHealthcare
IndustryBiotechnology
CountryUnited States
ExchangeNasdaqGS
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Performance
| Period | Return % | Value Change |
|---|---|---|
| 1 Day | -0.23% | -2.12 US$ |
| 5 Days | -3.58% | -34.25 US$ |
| 1 Month | +14.34% | +115.55 US$ |
| 6 Months | +44.19% | +282.34 US$ |
Analyzing Market with AI
Evaluating the last 30 days of history and fundamental metrics of REGN...
Key Statistics
Market Cap
95.24B
P/E Ratio
20.35
Div Yield
0.41%
52W High
$991.73
52W Low
$591.52
Analyst Consensus
ConsensusBuy
Bullish1967.9%
Neutral932.1%
Bearish00.0%
52W Analyst Price Targets
Min Target
$812.00
$812.00
Max Target
$1175.00
$1175.00
Current$921.22
Avg Target$991.00
Analyst Recommendations
Target Price:$991.00($812.00 - $1175.00)
Looking for more stocks? Explore them in the screener
Community Thoughts
Share your analysis and sentiment on REGN
Join the community to share your analysis
Latest News for REGN

Has Vertex Stock Become A Different Bet?
Trefis•Nov 20, 2026, 12:28 PM
Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,050 From $850
MT Newswires•Nov 20, 2026, 12:10 PM

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance
Pharma Voice•Nov 19, 2026, 09:52 PM

Alnylam (ALNY) Stock Looks Undervalued As Shares Fell 68%
Simply Wall St.•Nov 19, 2026, 06:17 PM

2 Growth Stocks to Buy in November Without Any Hesitation
Motley Fool•Nov 19, 2026, 06:03 PM

Alnylam Pharmaceuticals (ALNY) Stock Dropped, So What Is Driving Attention Now?
Simply Wall St.•Nov 19, 2026, 04:08 PM

With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
BioPharma Dive•Nov 19, 2026, 03:10 PM

REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis
Zacks•Nov 19, 2026, 02:42 PM
Goldman Sachs Adjusts Regeneron Pharmaceuticals PT to $1,115 From $1,110
MT Newswires•Nov 19, 2026, 02:01 PM

Regeneron Wins FDA Nod For Livsayis, 4x-Year GMG Shot
Benzinga•Nov 19, 2026, 01:10 PM